Devimistat

N/A

Report date: 2024/07/05 11:15:22
NME

Base Information

Drug NameDevimistat
Drug Alias NameBylantraCPI-613
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPyruvate dehydrogenase complex inhibitorsOxoglutarate dehydrogenase complex inhibitors
TargetsOxoglutarate dehydrogenase complexPyruvate dehydrogenase complex
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaMyelodysplastic Syndromes +[57] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCornerstone Pharmaceuticals IncOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesThe University Of Texas MD Anderson Cancer CenterCornerstone Pharmaceuticals Inc +[6] 
Inactive CompaniesAtlantic Health System IncSidney Kimmel Cancer Center At Thomas Jefferson UniversityUniversity Of Michigan Rogel Cancer Center
Active IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaLung Neoplasms +[32] 
Inactive IndicationsMyelodysplastic SyndromesNeoplasm MetastasisSmall Cell Lung Carcinoma +[25] 

Other Information

ATC CodeN/A
Related LinksN/A